| 本文已被：浏览 1359次 下载 1437次 |
码上扫一扫！ |
|
|
| 芪地糖肾方治疗DKD微量蛋白尿及对尿PCX、LAP的影响 |
|
徐婧1, 柳红芳2, 苗桂珍3, 曹柏龙3, 李侠2, 于博睿1, 王丹1, 连心逸1
|
|
1.北京中医药大学, 北京 100029;2.北京中医药大学东直门医院, 北京 100700;3.北京中医药大学东直门医院通州院区, 北京 101121
|
|
| 摘要: |
| [目的] 研究芪地糖肾方治疗气阴两虚、瘀热阻络型糖尿病肾脏病（DKD）微量白蛋白尿期患者的临床疗效和对尿足细胞标志蛋白（PCX）、亮氨酸氨基肽酶（LAP）的影响。[方法] 选取60例符合纳入标准的气阴两虚、瘀热阻络型DKD微量白蛋白尿期患者随机分为两组。治疗组予基础治疗（降血糖、降血压、降血脂、饮食指导）和芪地糖肾方，对照组予基础治疗和等剂量安慰剂。比较两组临床疗效、中医证候疗效以及尿微量白蛋白肌酐比值（ACR）、血糖、血脂、尿PCX、尿LAP的变化情况。[结果] 治疗组临床疗效总有效率明显比对照组高（P<0.05）；治疗组中医证候疗效总有效率明显比对照组高（P<0.05）；治疗组尿ACR差值、尿LAP差值较对照组有统计学差异（P<0.05）。[结论] 芪地糖肾方治疗气阴两虚、瘀热阻络型DKD微量白蛋白尿期患者疗效显著，可降低尿蛋白，降低尿LAP。 |
| 关键词: 微量蛋白尿 芪地糖肾方 糖尿病肾脏病 尿PCX 尿LAP |
| DOI：10.11656/j.issn.1673-9043.2020.03.09 |
| 分类号:R587.2 |
| 基金项目:国家中医临床研究基地业务建设科研专项（JDZX2015305）；北京市科委十病十药研发项目（Z161100001816003）；北京中医药大学2018年度在读研究生项目（2018-JYBZZ-XS166）。 |
|
| Effects of Qidi Tangshen Formulation in treating DKD patients with microalbuminuria and its effects on urine PCX and LAP |
|
XU Jing1, LIU Hongfang2, MIAO Guizhen3, CAO Bailong3, LI Xia2, YU Borui1, WANG Dan1, LIAN Xinyi1
|
|
1.Beijing University of Chinese Medicine, Beijing 100029, China;2.Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700, China;3.Tongzhou District of Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 101121, China
|
| Abstract: |
| [Objective] To study the clinical effect of Qidi Tangshen Formulation on microalbuminuria and its influence on urine PCX and LAP in type diabetic kidney disease with qi-yin deficiency and blood stasis and heat blocking collaterals.[Methods] Sixty patients of DKD with deficiency of both qi and yin and obstruction of blood stasis and heat were randomly divided into the two groups. The treatment group received basic treatment (lowering blood sugar,lowering blood pressure,lowering blood lipid and diet guidance) and Qidi Tangshen Formulation,while the control group received basic treatment and placebo. The clinical curative effect,traditional Chinese medicine syndrome curative effect and the change of urine ACR,blood sugar,blood fat,urine PCX and urine LAP were compared between the two groups.[Results] The total effective rate of the treatment group was significantly higher than that of the control group (P<0.05). The total effective rate of TCM syndrome integral in treatment group was significantly higher than that in control group (P<0.05). The difference of ACR and LAP in urine of the treatment group was significantly different from that of the control group (P<0.05).[Conclusion] Qidi Tangshen Formulation has a significant effect on DKD patients with qi-yin deficiency and blood stasis and heat blocking collaterals,which can reduce urine protein and urine LAP. |
| Key words: microalbuminuria Qidi Tangshen Formulation diabetic kidney disease urine PCX urine LAP |
